Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
19hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback